{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"21.4","value":"15.9"},{"comment":"The upper limit of 95% confidence interval was not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events","groupId":"OG001","lowerLimit":"4.2","upperLimit":"NA","value":"22.1"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"20.7","value":"6.2"},{"groupId":"OG003","lowerLimit":"2.8","upperLimit":"13.3","value":"7.8"},{"comment":"The lower and upper limit 95% confidence interval were not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"15.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"DoR defined as the time from first documented evidence of PR or better until disease progression (PD) among responders according to the 2016 IMWG response criteria or death due to any cause. PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\<200 mg/24 h. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>=5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg per 24 h).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose on Day 1 of every 3 weeks (Q3W) as a 30-60 minute intravenous (IV) infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG000","title":"Arm A: Belantamab Mafodotin 2.5 Milligram (mg)/Kilogram (kg) Every 3 Weeks (Q3W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q3W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG001","title":"Arm B: Belantamab Mafodotin 1.9 mg/kg Q3W"},{"description":"Participants with RRMM received belantamab mafodotin as 2.5 mg/kg dose on Day 1 of every 6 weeks (Q6W) as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG002","title":"Arm C: Belantamab Mafodotin 2.5 mg/kg Every 6 Weeks (Q6W)"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death.","id":"OG003","title":"Arm D: Belantamab Mafodotin 1.9 mg/kg Q6W"},{"description":"Participants with RRMM received belantamab mafodotin as 1.9 mg/kg dose on Day 1 of Q6W as a 30-60 minute IV infusion until confirmed disease progression, unacceptable toxicity or death. For this arm, dose modification decisions were determined by the results of the Ocular Surface Disease Index (OSDI) questionnaire or VA assessments using Snellen chart. The OSDI scale assesses the severity of eye symptoms and their impact and Snellen chart is for the assessment of visual acuity.","id":"OG004","title":"Arm E: Belantamab Mafodotin 1.9 mg/kg Q6W (Based on OSDI + Visual Acuity [VA] Assessment)"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat Population. Only those participants with confirmed PR or better (i.e., PR, VGPR, CR and sCR) have been analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 152 weeks","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}